Literature DB >> 10210324

Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells.

S E Nicholls1, S Winter, R Mottram, J A Miyan, A D Whetton.   

Abstract

Flt3 ligand elicits a variety of effects on early hemopoietic progenitors by occupying its cognate receptor, Flt3, a member of the type III tyrosine kinase receptor family. The cytokines macrophage colony-stimulating factor (M-CSF) and stem cell factor (SCF) bind to related members of this tyrosine kinase receptors family, c-fms and c-kit, respectively. The relative effects of the cytokines M-CSF, SCF, and Flt3L on the proliferation and development of the late myeloid progenitors granulocyte-macrophage colony-forming cells (GM-CFC) were investigated. Distinct biologic responses were stimulated by ligand binding to these different tyrosine kinase receptors in enriched GM-CFC. M-CSF stimulated GM-CFC to proliferate and develop into macrophages. SCF, on the other hand, stimulated GM-CFC to develop into neutrophils. Flt3 ligand had a relatively small proliferative effect on enriched GM-CFC compared to SCF and M-CSF and had no ability to either stimulate colony formation or synergize with these two cytokines in promoting DNA synthesis, colony formation, or expansion in liquid culture. Flt3 ligand, however, was capable of maintaining the clonogenic potential of GM-CFC and acted as an anti-apoptotic agent as assessed using the Annexin-V apoptosis assay. GM-CFC cultured in Flt3 ligand eventually formed macrophages and neutrophils in liquid culture. Labeling with the membrane-associated cell tracker dye PKH26 indicated that the majority of the enriched GM-CFC responded to Flt3 ligand by undergoing limited proliferation and macrophage development, whereas other cells survived but did not proliferate and differentiate into macrophages. Thus, Flt3 ligand promoted survival and stimulated development without proliferation in primary-enriched myeloid progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210324     DOI: 10.1016/s0301-472x(98)00072-1

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Dendritic cells take on more tasks in the liver?

Authors:  Jeremy S Duffield
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

Review 2.  Bench to bedside targeting of FLT3 in acute leukemia.

Authors:  Keith W Pratz; Mark J Levis
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

3.  Induced expression and association of the Mona/Gads adapter and Gab3 scaffolding protein during monocyte/macrophage differentiation.

Authors:  Caroline Bourgin; Roland P Bourette; Sylvie Arnaud; Yan Liu; Larry R Rohrschneider; Guy Mouchiroud
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  FLT3/ITD AML and the law of unintended consequences.

Authors:  Mark Levis
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

Review 5.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

6.  Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization.

Authors:  Yushuo Gao; Yisheng Zhong; Yanji Zhu; Anna M Demetriades; Yujuan Cai; Jikui Shen; Qing Lu; Xi Shen; Bing Xie
Journal:  J Ophthalmol       Date:  2018-05-03       Impact factor: 1.909

7.  Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia.

Authors:  Christine Servet-Delprat; Sylvie Arnaud; Pierre Jurdic; Serge Nataf; Marie-France Grasset; Caroline Soulas; Chantal Domenget; Olivier Destaing; Aymeric Rivollier; Magali Perret; Christiane Dumontel; Daniel Hanau; Gary L Gilmore; Marie-Françoise Belin; Chantal Rabourdin-Combe; Guy Mouchiroud
Journal:  BMC Immunol       Date:  2002-10-24       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.